Edition:
United States

CytRx Corp (CYTR.PH)

CYTR.PH on Philadelphia Stock Exchange

0.40USD
23 Jan 2017
Change (% chg)

-- (--)
Prev Close
$0.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,614
52-wk High
$3.62
52-wk Low
$0.37

Select another date:

Tue, Nov 29 2016

BRIEF-Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

* Cytrx-Reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

BRIEF-Cytrx presents positive interim results from on-going clinical trial

* Cytrx says dose-limiting toxicities were not observed in either cohort, and no clinically significant cardiac toxicities were seen

BRIEF-Cytrx Q3 loss $0.13/shr

* Cytrx Corp - during Q3, embarked on a plan to reduce spending until additional results from Aldoxorubicin phase 3 STS clinical trial are available

BRIEF-Cytrx completes enrollment in lung cancer mid-stage study

* Says Completion Of Enrollment In Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Patients With Second Line small cell lung cancer

BRIEF-Cytrx reports loss per share of $0.27 for Q2 2016

* Q2 loss per share $0.27 Source text for Eikon: Further company coverage:

Select another date: